US 9957259
Selective HDAC1 and HDAC2 inhibitors
granted A61KA61K31/4045A61K31/4709
Quick answer
US patent 9957259 (Selective HDAC1 and HDAC2 inhibitors) held by Regenacy Pharmaceuticals, Inc. expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Regenacy Pharmaceuticals, Inc.
- Grant date
- Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/4045, A61K31/4709, A61K31/496, A61K31/498